Cardiac Prosthetic Devices Market Report 2026

Cardiac Prosthetic Devices Market Overview

• Cardiac Prosthetic Devices market size has reached to $9.09 billion in 2025 • Expected to grow to $15.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Rising Cardiovascular Disease Rates Drive Growth in Cardiac Prosthetic Devices • Market Trend: Abbott Introduces TriClip G4 System For Minimally Invasive Tricuspid Valve Repair • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiac Prosthetic Devices Market?

Cardiac prosthetic devices are medical devices designed to support or replace the heart's function or its components. These devices treat various cardiac conditions and are essential in managing patients with heart failure or structural heart problems. The main types of cardiac prosthetic devices are valves and pacemakers. Valves refer to artificial devices implanted in the heart to replace malfunctioning natural heart valves. The various applications include surgery and research and are used in several end users such as hospitals, clinics or cardiac centers, ambulatory surgical centers, and other end-users.

What Is The Cardiac Prosthetic Devices Market Growth Forecast?

The cardiac prosthetic devices market size is expected to see rapid growth in the next few years. It will grow to $15.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to aging global population, increasing demand for minimally invasive cardiac treatments, rising burden of heart failure cases, expanding access to advanced cardiac care in emerging markets, growing focus on early intervention for structural heart diseases. Major trends in the forecast period include rising adoption of minimally invasive cardiac prosthetic procedures, increasing demand for advanced heart valve replacement solutions, growing use of cardiac prosthetics in heart failure management, expansion of transcatheter cardiac device applications, increasing focus on long-term device durability and patient outcomes.

Global Cardiac Prosthetic Devices Market Segmentation

1) By Type: Valves, Pacemakers 2) By Applications: Surgery, Heart Valve Replacement Procedures, Cardiac Rhythm Management 3) By End User: Hospitals, Clinics Or Cardiac Centers, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Valves: Mechanical Valves, Tissue Valves, Transcatheter Heart Valves 2) By Pacemakers: Single-Chamber Pacemakers, Dual-Chamber Pacemakers, Biventricular Pacemakers

What Is The Driver Of The Cardiac Prosthetic Devices Market?

The prevalence of cardiovascular diseases is expected to propel the growth of the cardiac prosthetic devices market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart attacks, and strokes. The prevalence of cardiovascular diseases is due to unhealthy lifestyles, high rates of obesity, poor diet, lack of physical activity, high stress levels, and an aging population. Cardiac prosthetic devices play a significant role in managing cardiovascular diseases by supporting or replacing the heart's function or its components. For instance, in January 2024, according to the data published by the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the prevalence of cardiovascular diseases is driving the growth of the cardiac prosthetic devices industry.

Key Players In The Global Cardiac Prosthetic Devices Market

Major companies operating in the cardiac prosthetic devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, BIOTRONIK SE & Co KG, Terumo Corporation, Lepu Medical Technology Beijing Co Ltd, Abiomed Inc, LivaNova PLC, Meril Life Sciences Pvt Ltd, MicroPort Scientific Corporation, CryoLife Inc, LifeTech Scientific Corporation, Venus Medtech Hangzhou Inc, Braile Biomedica, AtriCure Inc, Aortic Innovations Inc, Pacetronix Limited, TTK Healthcare Limited, Kawasumi Laboratories Inc

Global Cardiac Prosthetic Devices Market Trends and Insights

Major companies operating in the cardiac prosthetic devices market are focusing on minimally invasive transcatheter therapies, such as transcatheter edge‑to‑edge repair (TEER) systems, which are catheter-delivered clip implants designed to grasp and approximate the leaflets of a dysfunctional valve (for instance, the tricuspid valve), thereby reducing regurgitation without open-heart surgery. For instance, in April 2024, Abbott, a US-based medical‑technology company, launched its TriClip G4 System, a TEER device for treating severe tricuspid regurgitation. The TriClip G4 System is delivered via a femoral‑vein catheter; its clip arms open and close to grasp the valve leaflets, and it supports multiple clips to achieve optimal reduction of leakage.

What Are Latest Mergers And Acquisitions In The Cardiac Prosthetic Devices Market?

In October 2024, Johnson & Johnson, a US-based diversified medical-technology and pharmaceutical company, acquired V-Wave Ltd. for an undisclosed amount; with this acquisition, Johnson & Johnson aimed to strengthen and broaden its cardiac prosthetic and structural-heart portfolio by adding V-Wave’s Ventura® implantable interatrial shunt for heart failure, thereby enhancing its offering of minimally invasive heart implants and improving treatment options for patients with advanced heart failure. V-Wave Ltd. is an Israel-based cardiovascular medical-device company that develops implantable interatrial shunt devices for the treatment of heart failure.

Regional Outlook

North America was the largest region in the cardiac prosthetic devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiac Prosthetic Devices Market?

The cardiac prosthetic devices market consists of sales of ventricular assist devices, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.